Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Paraganglioma × Blood Specimen Collection × CNS × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Endocrine 1 CNS 1

Conditions

Glioma 16 Glioblastoma 12 Brain Neoplasms 10 Neuroblastoma 3 Neoplasms 3 Astrocytoma 3 Sarcoma 2 Prostatic Neoplasms 2 Neurofibromatosis 1 2 Neoplastic Cells, Circulating 2 Meningioma 2 Lung Neoplasms 2 Breast Neoplasms 2 Wilms Tumor 1 Urinary Bladder Neoplasms 1 Stomach Neoplasms 1 Radiation Injuries 1 Pituitary Neoplasms 1 Pheochromocytoma 1 Paraganglioma 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Osteosarcoma 1 Oligodendroglioma 1 Neoplasms, Germ Cell and Embryonal 1 Neoplasm Recurrence, Local 1 Neoplasm Metastasis 1 Melanoma 1 Medulloblastoma 1 Lymphoma, Follicular 1

Interventions

3-Iodobenzylguanidine 7 lutetium Lu 177 dotatate 6 gallium Ga 68 dotatate 5 Specimen Handling 4 Magnetic Resonance Spectroscopy 4 Temozolomide 3 olaparib 2 belzutifan 2 anlotinib 2 Phenoxybenzamine 2 Nivolumab 2 Fluorodeoxyglucose F18 2 Everolimus 2 Biopsy 2 3-fluorobenzylguanidine 2 177Lu-octreotide, DOTA(0)-Tyr(3)- 2 talazoparib 1 spartalizumab 1 pazopanib 1 lanreotide 1 guadecitabine 1 fludarabine phosphate 1 copper dotatate CU-64 1 cixutumumab 1 cabozantinib 1 atezolizumab 1 Vorinostat 1 Sunitinib 1 Salts 1 Radiosurgery 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06444607 2024-11-21

HEPHESTOS

Radboud University Medical Center

Paraganglioma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡